Anafranil

Basic Anafranil information

• INN (international nonproprietary name): clomipramine
• Brand names available in the United Kingdom: Anafranil (capsules).
• ATC code: N06AA04
• Forms and dosages: capsules 10 mg, 25 mg and 50 mg.
• Manufacturers: Novartis (originator); generic manufacturers include Sun Pharma and Teva.
• Registration status in the United Kingdom: Prescription-only medicine; licensed for depressive illness and obsessional and phobic states.
• OTC / Rx classification: Prescription-only medication (Rx).

Legal status and availability in the UK

In our online pharmacy, Anafranil is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Patients want to know what happens in NHS clinics when SSRIs fail.

Within NHS services, Anafranil is usually reserved for people whose OCD does not respond adequately to high‑dose SSRIs or to CBT augmentation.

Responders typically need slower titration and longer optimisation than with SSRIs.

Common tolerability issues raised at clinic follow‑ups include sedation, weight gain and anticholinergic symptoms such as dry mouth and constipation.

ECG monitoring before and during dose escalation is advisable when clomipramine is started.

Prescriptions come from GPs or specialists and are supplied via community or hospital pharmacies.

Electronic repeat dispensing and the NHS app are commonly used for repeat supplies and reminders in many areas.

• Outcomes: Response and remission rates improve in refractory cases but often after slower titration.
• Tolerability: Sedation, dry mouth, constipation and weight gain are frequently reported and may prompt dose adjustment.
• Monitoring steps: Baseline ECG, blood pressure lying/standing, review at 2–4 weeks and stepped dose changes with ongoing review.

Indications and expanded uses

One common question is whether Anafranil is used only for OCD.

In the UK, clomipramine is licensed for depressive illness, obsessional and phobic states, and as an adjunct in cataplexy associated with narcolepsy.

In NHS practice it is mainly used for obsessive–compulsive disorder, particularly when CBT plus an SSRI has failed, and is sometimes used off‑label for severe panic disorder under specialist oversight.

Prescribers should document the clinical rationale and discuss higher side‑effect rates versus SSRIs when using clomipramine off‑label.

• Licensed indications: depressive illness, obsessional (including obsessive–compulsive disorder) and phobic states, adjunct in cataplexy.
• Off‑label uses: some severe anxiety presentations such as panic disorder — requires informed consent and specialist oversight.
• Contraindications to check: Recent myocardial infarction, concurrent MAOI use, severe liver disease and known hypersensitivity to tricyclics.

Standard initial OCD dosing typically begins at 25 mg at bedtime with gradual titration, and clinicians must outline monitoring plans to patients.

Composition and brand landscape

People often ask which brands and strengths are available in the UK.

The active ingredient is clomipramine hydrochloride, classified under ATC code N06AA04 among tricyclic antidepressants.

The most commonly recognised brand is Anafranil, supplied as capsules in 10 mg, 25 mg and 50 mg strengths.

Generic clomipramine is available from manufacturers such as Sun Pharma and Teva.

• Brand: Anafranil — capsules 10 mg, 25 mg, 50 mg.
• Generics: available from Sun Pharma, Teva and others; substitution is common in community and hospital pharmacies.

Prescribers can request brand‑specific supply if clinically necessary, and pharmacists often substitute generics where appropriate.

Contraindications and special precautions

Patients frequently worry about heart problems and pregnancy when starting Anafranil.

Absolute contraindications include recent myocardial infarction, known hypersensitivity to clomipramine or other tricyclics, and concurrent use of MAO inhibitors.

Other high‑risk situations needing caution are prior arrhythmia, conduction defects, severe liver disease, history of seizures, closed‑angle glaucoma and urinary retention or prostatic hypertrophy.

Elderly patients should begin at lower doses with slow titration and ECG monitoring because anticholinergic and cardiac risks are amplified.

Pregnancy and breastfeeding data are limited and require joint assessment with obstetric and paediatric teams; avoid abrupt discontinuation.

Driving and alcohol advice: do not drive until you know how Anafranil affects alertness, and avoid alcohol as it increases sedation and orthostatic effects.

Prescribers and pharmacists should follow a checklist before initiation.

• Baseline ECG and review during dose escalation.
• Measure blood pressure lying and standing at baseline and early follow‑up.
• Reconcile medications to exclude MAO inhibitors and other high‑risk combinations.
• Consider pregnancy test if clinically relevant and document informed consent for off‑label uses.

Dosage guidelines

Many patients ask how fast the dose will be increased and what target dose is expected.

Standard adult OCD regimens start at 25 mg nightly and increase by about 25 mg increments as tolerated.

Typical maintenance doses range between 100 mg and 250 mg per day in divided doses, with a maximum commonly cited at 250 mg daily.

Titration is usually spread over 2–3 weeks for the initial phase, then adjusted over subsequent weeks to clinical response.

Elderly patients start at the lowest adult dose and are titrated slowly with close review and ECG monitoring.

There is no formal universal dose adjustment for liver or kidney impairment, so clinicians exercise caution and monitor plasma levels or clinical status where available.

Missed dose advice is straightforward: take as soon as remembered unless it is close to the next dose and do not double doses.

Interactions overview

Patients often worry about combining Anafranil with other medicines or OTC remedies.

Concurrent MAO inhibitor use is contraindicated because of the severe risk of serotonin syndrome.

Combining clomipramine with other serotonergic medications — SSRIs, SNRIs, triptans — increases the risk of serotonin syndrome, and co‑prescription must be managed carefully.

Co‑use with QT‑prolonging drugs and certain antiarrhythmics raises cardiac risk and warrants ECG monitoring.

Anticholinergic agents such as some antihistamines and antimuscarinics will compound dry mouth, constipation and urinary retention.

Alcohol increases sedation and orthostatic hypotension; sympathomimetics in OTC cold remedies can also cause adverse interactions.

• High‑risk drug pairs: MAO inhibitors, certain antipsychotics and class IA/III antiarrhythmics.
• Food/drink: Avoid alcohol until stable; heavy caffeine may worsen tremor or anxiety.
• Monitoring actions: ECG and electrolytes when combining with QT‑prolonging agents; medication reconciliation at each review.

Drug interactions are a common cause of adverse events, so thorough medication reconciliation is essential.

Comparable medicines and preferences

Many clinicians and patients want a quick comparison between clomipramine and SSRIs.

NHS first‑line treatments for OCD are high‑dose SSRIs such as sertraline, fluoxetine and paroxetine combined with CBT.

Clomipramine is typically a second‑line or adjunct option when SSRIs fail to achieve adequate response.

Alternatives include sertraline, fluoxetine, paroxetine (SSRIs) and imipramine among other TCAs, each with distinct tolerability profiles.

Pros of clomipramine are its robust anti‑obsessional efficacy in refractory cases and a long evidence base supporting its use.

Cons include higher anticholinergic effects, increased cardiac monitoring burden and higher discontinuation due to side effects.

A practical decision checklist for clinicians should include prior SSRI trials, engagement with CBT, baseline cardiac evaluation, comorbid epilepsy or urinary retention and pregnancy plans.

For many UK patients, SSRIs remain preferred initially because of better tolerability; clomipramine is reserved for specialist settings or refractory illness.

Frequently asked questions

Q: Is Anafranil available on the NHS?

A: Yes — Anafranil is prescription‑only and is usually available via GP or specialist prescription, although local formulary decisions may affect prescribing.

Q: How long until I notice improvement?

A: Some people notice initial change within 2–4 weeks, but meaningful improvement in OCD usually takes 8–12 weeks at an effective dose with gradual titration.

Q: What side effects should I expect?

A: Common effects include drowsiness, dry mouth, constipation, dizziness and weight gain; report palpitations, fainting or severe dizziness to NHS 111 or your prescriber immediately.

Q: Can I drink alcohol or drive?

A: Avoid alcohol while establishing stability and do not drive until you know how Anafranil affects your alertness and reaction times.

Guidelines for proper use

People starting Anafranil often ask what their pharmacist will tell them at dispensing.

Pharmacist counselling should cover indication and expected timeline, the start‑low‑go‑slow titration approach, and clear dosing schedules.

Advice on managing common side effects includes sipping fluids for dry mouth, using bulk‑forming fibre and regular exercise for constipation and avoiding alcohol to reduce sedation.

Patients must be instructed on warning signs such as chest pain, fainting, severe dizziness, confusion or signs of serotonin syndrome and to seek urgent medical advice if these occur.

Monitoring protocol usually includes baseline ECG, blood pressure lying and standing, review at 2–4 weeks and reassessment after dose changes.

Pharmacists should signpost to NHS resources, encourage Yellow Card reporting for adverse reactions and offer medicine use reviews or electronic reminders.

• Baseline checks: ECG, medication reconciliation and BP lying/standing.
• Counselling script: Start 25 mg at night, titrate by 25 mg steps, expect 8–12 weeks for effect, manage common side effects and avoid alcohol until stable.
• Follow‑up schedule: Review at 2–4 weeks, again after dose increases and periodic cardiac monitoring as indicated.

Storage advice: store below 25°C, protected from light and moisture, and keep in the original packaging.

Delivery across the United Kingdom